<DOC>
	<DOCNO>NCT02046928</DOCNO>
	<brief_summary>This study ass efficacy , safety pharmacodynamic marker study drug , A6 , patient CLL small lymphocytic lymphoma ( SLL ) .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy A6 Patients With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>In patient diagnosed CLL SLL , study medication inject subcutaneously two time day outpatient set 6 cycle ( 28 day = 1 cycle ) prior primary endpoint assessment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Confirmed diagnosis CLL SLL base IWCLL Criteria Measurable evaluable disease base IWCLL criterion Previously untreated patient counsel approve alternative therapeutic option . Not candidate fludarabine/cyclophosphamide/rituximab ( FCR ) preference receive chemotherapy . Eastern Cooperative Oncology Group ( ECOG ) status 02 . Adequate bone marrow , renal , liver , cardiac pulmonary function . Life expectancy great equal 6 month . Receipt cancer therapy , immunomodulatory drug therapy immunosuppressive therapy within 4 week prior 1st dose . Receipt corticosteroid &gt; 20 mg/day within 4 week prior to1st dose Major surgery radiation within 4 week prior 1st dose Presence uncontrolled infection require systemic therapy Active second malignancy nonmelanoma skin cancer Uncontrolled autoimmune anemia thrombocytopenia Receipt investigational agent within 4 week prior 1st dose Pregnant lactate female Any severe , acute chronic medical psychiatric condition , lab abnormality may increase risk associate trial participation , study drug administration interfere informed consent process compliance requirement trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
</DOC>